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Jaap Jan Boelens,1 Vanderson Rocha,2 Mieke Aldenhoven,1 Robert Wynn,3 Anne O’Meara,4
Gerard Michel,5 Irina Ionescu,6 Suhag Parikh,7 Vinod K Prasad,7 Paul Szabolcs,7
Maria Escolar,8 Eliane Gluckman,9 Marina Cavazzana-Calvo,10 Joanne Kurtzberg,7 on
behalf of EUROCORD, Inborn error Working Party of EBMT and Duke UniversityAllogeneic stemcell transplantation (SCT) is consideredeffective in preventing disease progression in patientswith
Hurler syndrome (HS). Unrelated umbilical cord blood (UCB) grafts are suggested as an alternative to bone mar-
row (BM) or peripheral blood stem cells (PBSC).We studied 93HS patients receiving anUCB graft to analyze risk
factors for outcomes. The median time from diagnosis to transplant was 4.6 months, median follow-up was 29
months, and median number of nucleated CB cells infused was 7.6  107/kg. Most of the patients received 1 or
2 HLA disparate grafts, and the most frequently used conditioning regimen was cyclophosphamide 1 busulfan
(Bu/Cy). All patients received anti-T cell antibody. At post transplant day160, the cumulative incidence of neutro-
phil engraftment was 85%. A younger age at transplant and a higher CD341 dose at infusion were favorably asso-
ciated with engraftment.With the exception of 2 patients, all engrafted patients achieved full and sustained donor
chimerism. The 3-year event-free survival (EFS) and 3-year overall survival (OS) rates were 70% and 77%, respec-
tively. In amultivariate analyses, useofBu/Cy anda shorter interval fromdiagnosis to transplantwerepredictors for
improved EFS rate (82% for patients transplantedwithin 4.6months after diagnosis compared to 57% for the rest).
Improved outcomes from early transplantation and immediate availability of CB unit lead us to conclude that CB
transplantation is a beneficial option, which should be considered expediently for children with HS.
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Hurler syndrome (HS) is the most severe pheno-
type in the spectrum of mucopolysaccharidosis type I
(MPS I), a type of lysosomal storage disorder. These
patients develop progressive and ultimately fatal
multisystem deterioration, including psychomotor
retardation, severe skeletal manifestations, and life-
threatening cardiac and pulmonary complications be-
cause of severe deficiency or complete absence of the
lysosomal enzyme alpha-L-iduronidase [1]. Because
enzyme replacement therapy (ERT), available for
MPS I patients since 2003, is not able to prevent cen-
tral nervous system deterioration, allogeneic stem cell
transplantation (SCT) is still considered as the treat-
ment of choice in patients with HS [2,3].
Worldwide, over 500 SCTs have been performed
in HS patients, making HS the most frequently trans-
planted inborn error of metabolism (IEM) [4,5].
Although significant successful clinical results have
been reported in HS patients after SCT, provided
the transplantation was performed early in life [6],
the success of SCT has been limited by donor
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rism, and treatment-related morbidity and mortality
(TRM) [7]. To reduce these limitations, a risk factor
analysis was performed in HS patients registered in
the European Blood and Marrow Transplantation
(EBMT) database [7]. In this European retrospective
study, both T cell depletion and reduced-intensity
conditioning (RIC) regimen were found to be risk fac-
tors for graft failure, whereas busulphan (Bu) pharma-
cokinetic targeting protected against graft failure.
Recent studies, using cord blood (CB) as a stem cell
source for SCT in IEM, showed high rates of full do-
nor chimerism associated with normal enzyme levels
postengraftment [8-11]. Because full donor chimerism
and normal enzyme levels are suggested to be associ-
ated with a superior neurocognitive outcome after
SCT, CB has been proposed as an alternative option
or even preferential stem cell source in HS patients
[6]. Still, little is known about the risk factors influenc-
ing various measures of outcome in HS patients after
unrelated CB transplantation.
To be able to study a large series of HS patients
and to perform a risk factor analysis for myelogenous
engraftment and event-free survival (EFS) after unre-
lated CB transplantation, we conducted a collaborative
retrospective analysis of umbilical cord blood trans-
plantation (UCBT) performed in HS patients treated
in multiple centers in Europe and at Duke University
in the United States.PATIENTS AND METHODS
Data Collection
This retrospective analysis is based on data
reported to the Eurocord Registry from European
and non-European centers through a standardized
questionnaire that includes information about the
patients, CB units, diseases, and transplant outcomes.
Data from Duke University was collected for all con-
secutive transplants performed and registered to the
institutional stem cell transplantation database and
the Center for International Blood and Marrow
Transplant Research (CIBMTR). The collected infor-
mation was reviewed by 2 physicians and checked for
computerized errors to ensure data quality. Overlaps
between Eurocord database and Duke University
were checked to eliminate overlap or duplicative re-
porting. All parents and or legal guardians of patients
gave informed consent for UCBT according to the
Declaration of Helsinki. The present study was ap-
proved by the Eurocord and Working Party Inborn
Errors of European Blood and Marrow transplant
group (EBMT). Patients treated at Duke University
Medical Center were enrolled on treatment protocols
approved by the hospital’s institutional review board.
Fourteen of the Duke patients were enrolled on theCord Blood Transplantation Study (COBLT) sup-
ported by the National Heart, Lung Institute of the
National Institutes of Health.
Criteria of Patient’s Selection
The following criteria were required: (1) diagnosis
of HS was confirmed by an increased urinary
glycosaminoglycan excretion, a deficiency or absence
of alpha-L-iduronidase in peripheral blood leukocytes,
and the clinical phenotype; (2) transplantation with
a nonexpanded, single, unrelatedCB unit; (3) complete
clinical data with at least 3 months of posttransplant
follow-up; (4) transplants using myeloablative condi-
tioning regimen performed between 1995 and 2007.
Definitions and Endpoints
The main endpoints were (1) EFS, defined as the
time from transplantation to autologous reconstitu-
tion, graft failure, second transplant, or death; (2)
overall survival (OS), defined as the time from trans-
plantation until the date of death. Other endpoints
were (1) neutrophil recovery and (2) acute or chronic
graft-versus-host disese (aGVHD, cGVHD). Neutro-
phil recovery was defined as the first day of achieving
a neutrophil count of $0.5  109/L for 3 consecutive
days, and graft failure as no sign of neutrophil recovery
or transient engraftment of donor cells within 60 days
after transplantation or second transplants. HLA
matching was scored using low or intermediate resolu-
tion typing for HLA Class I A and B and high-
resolution typing for DRB1. Chimerism data was
available during the first 3 months after UCBT and
at last assessment of the patients. Full donor chimerism
(on whole blood) was defined as the presence of more
than 95% donor-derived hematopoietic cells, mixed
chimerism if .10% and\95% were of donor origin
and autologous recovery if \10% of cells were
donor-derived cells. Data on the methodology of chi-
merism detection was not available. Enzymes were
regarded normal when levels were normal according
to the institutional reference range and heterozygous
when the value was below the lower limit of normal
but not within the patient range. It was called hetero-
zygous when carriers of the disease are having
subnormal enzyme levels as well. aGVHD at day 100
was diagnosed and graded according to published
criteria [12] and cGVHD at 2 years was graded accord-
ing to standard criteria [13] and evaluated in pati-
ents who survived at least 100 days with sustained
engraftment.
Statistical Analysis
The duration of follow-up was the time to the last
assessment for survivors. To analyze risk factors for
outcomes, we considered variables associated with
the recipient (median age at transplant, median weight
Table 1. Baseline Patient, Donor, and Transplantation
Characteristics
Baseline Characteristics*
Patient characteristics
n % Missing
Overall 93
Sex (male/female) 48/45 52 0
CMV serology (negative) 64 78 11
Previous transplant 2 2 0
Median Range
Age at SCT (years) 1.3 0.2-5 0
Interval diagnosis-transplant (months) 4,6 1-35 1
Follow-up post- SCT (months) 29 3-140 0
Weight (kg) 11.5 5-22 2
Donor characteristics
n % Missing
Overall 93
HLA-matching 3
6/6 13 14
5/6 49 54
4/6 24 27
3/6 4 5
ABO compatibility 36 44 11
Median Range
Cell dose
Collected NC (107/kg) 10.4 3-33 2
Collected CD34+ (105/kg) 3.6 0.5-130 3
Infused NC (107/kg) 7.6 2-27 2
Infused CD34+ (105/kg) 2.6 0.4-104 3
Transplantation characteristics
Median Range Missing
Year of SCT 2004 1995 - 2007 0
n %
Overall 93
Conditioning regimen 4
Bu/Cy 77 87
Other 12 13
GVHD prophylaxis 5
CSA ± Pred 67 75
CSA/MMF 13 15
CsA/MTX 8 10
Serotherapy (ATG: 85 or Campath: 4) 89 100 4
Bu indicates busulphan; CMV, cytomegalovirus; CsA, cyclosporine; Cy,
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megalovirus [CMV] serology status), the disease
(median interval time from diagnosis to transplant,
use of ‘‘enzyme replacement therapy’’ prior to trans-
plant (at least 4 doses), the CB unit (HLA-disparity,
and median collected and infused total nucleated cell
[TNC] and CD341 cell doses), and the transplant
(year of transplant, use of Bu/cyclophosphamide
(CY), and the type of GVHD prophylaxis). Because
of sample size, the median interval between diagnosis
and CBT, median collected and infused nucleated
cells, and CD341 were taken to dichotomize the
group. Cumulative incidence curves were used for
neutrophil recovery, aGVHD, and cGVHD in a com-
peting risk setting, because death is a competing event
[14]. Gray test was used for univariate comparisons
[15]. Probabilities of EFS and OS were calculated us-
ing the Kaplan-Meier estimate; the 2-sided log-rank
test was used for univariate comparisons.
Factors associated with a P-value\.10 by univari-
ate analysis (which are described in the Results section)
and other relevant factors such as HLA matching and
cell dose were included in multivariate analyses, using
Cox proportional hazards for EFS and OS, and pro-
portional subdistribution hazard regression model of
Fine and Gray for neutrophil recovery [16]. Then,
a stepwise regression was performed using a threshold
of .05. All tests were 2-sided. The type I error rate was
fixed at .05 for determination of factors associated with
time to event outcomes. Risk factor analysis for
aGVHD and cGVHD was not performed because of
the relative small number of events. Statistical analyses
were performed with SPSS (SPSS Inc., Chicago, IL)
and S-Plus (MathSoft, Inc, Seattle, WA) software
packages.cyclophosphamide; GVHD, graft-versus-host-disease; HLA, human leu-
kocyte antigen; kg, kilogram; MMF, mycophenolate mofetil; MTX, meth-
otrexate; NC, nucleated cells; Pred, prednisolone; SCT, stem cell
transplantation.
*CB transplantation was performed in the following centers: Duke (47),
Manchester (9), Utrecht (8), Dublin (4), Marseille (3), Barcelona (2),
London (2), Madrid (2), Mineapolis (2), Israel (2), Argentina (2), Japan
(2), Gent (1), Nancy (1), Paris (1), Padua (1), Prague (1), Helsinki (1),
Australia (1), New Zealand (1).RESULTS
Patients, Donor, and Transplant Characteristics
Ninety-three patients with HS receiving an unre-
lated CBT between 1995 and 2007 met the eligibility
criteria in the EUROCORD and Duke databases.
The baseline patient, donor, and transplantation char-
acteristics are shown in Table 1. Overall, the patients
were young and small, with a median age of 1.3 years
andmedian weight of 11.5 kg. Themajority of patients
were serologically negative for CMV pretransplant.
The majority of patients were transplanted with
HLA mismatched grafts at 1 (54%) or 2 (27%) loci.
Two patients had received a previous unsuccessful
BM transplant. A total of 40 patients of this report
have been previously published [7-10].
The majority of children were conditioned with
myeloablative chemotherapy using Bu/Cy with anti-
tyymocyte globulin (ATG) (89%) or Campath-1H.
All patients received cyclosporine (CsA) containingprophylaxis against GVHD with steroids (75%) as
the most common second agent. Given their small
size and young age, these patients were transplanted
with relatively large doses of cord blood cells, median
10.4 107 cells/kg at collection and 7.6  107 cells/kg
infused. Likewise, the delivered (infused) median
CD34 dose was 2.6  105/kg.
Neutrophil and Platelets Recovery and
Chimerism
Cumulative incidence function (CIF) of neutrophil
recovery at day 60 was 85%, with 82% engrafting at or
before day 42. Themedian time to neutrophil recovery
Table 2. Primary and Secondary Endpoints
Endpoints
Primary endpoints
n %
3-year OS 72 77
3-year EFS 65 70
Secondary endpoints n % Missing
Neutrophil recovery* 79 85 0
Chimerism (at latest follow-up) ‡
Full donor 56 97 7
Mixed 2 3
Enzyme levels‡
Normal 61 97 2
Heterozygous 2 3
CIF of acute GVHD (grade II-IV)) 29 31 0
(grade III-IV) ) 5 5
CIF of chronic
GVHD at 3 years¶
22 36 0
EFS indicates event-free survival; GVHD, graft-versus-host-disease;
OS, overall survival; CIF, cumulative incidence function.
*Median days 22 (range: 10–46).
‡Of patients alive and engrafted.
)Absent: 33 (38%), grade I: 26 (30%), grade II: 22 (25%), grade III: 3 (3%),
grade IV: 2 (2%).
¶Limited 12 (20%), extensive 10 (16%).
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of neutrophil recovery had a positive impact from (1)
younger age at SCT (95% for \1.3 years and 78%
for $1.3 years; P 5 .04); (2a) higher CD341 cell
dose at infusion (91% for .2.6  105/kg at infusion
and 81% for \2.6  105/kg at infusion; P 5 .004);
(2b) higher CD341 cell dose at collection (95% for
.3.6  105/kg at infusion and 79% for\3.6  105/
kg at infusion; P 5 .001); (3) year of transplantation
(\2004: 79% versus $2004: 91%, P 5 .05). Of note,
all 13 patients in this series receiving an HLA identical
(6 of 6) CB graft recovered neutrophil (median 22,
range: 10-46 days: same as for the whole group)
recovery compared to 82% for the remainder of
patients (P 5 ns). In multivariate analysis, younger
age at transplantation and high infused (postthaw)
CD341 cell dose were independent predictors of early
neutrophil recovery (P 5 .01 and P 5 .002, respec-
tively; Table 3).
Eleven patients experienced either autologous
reconstitution (n 5 6) or secondary graft failure
(n5 5) during the 3months afterUCBT. Four of these
patients subsequently died because of graft failure (3)
or disease progression (1). One patient is alive with dis-
ease. Six patients were retransplanted. Chimerism data
at 3 months posttransplant was available for 73 of the
79 engrafting patients, and showed that 65 were full
chimera, whereas 8 had mixed chimerism. At last
assessment, chimerism data was available for all 65
patients who were ‘‘alive and engrafted.’’ Sixty-four
of them were full chimeras, whereas 2 had mixed
but high chimerism (donor chimerism level of 90%
and 94% in whole blood cells). Normal alpha-L-
iduronidase enzyme level in the blood was found
in 97% of ‘‘alive and engrafted’’ patients. The
primary and secondary endpoints are further outlined
in Table 2.
aGVHD and cGVHD
CIF of aGVHD at day 100 was 31% 6 5%.
Twenty-five percent of the patients had a maximum
grade II, whereas 3% had grade III and 2% had grade
IV.Of themany variables analyzed, only the number of
TNC infused (20% for\7.6  107/kg versus 36% for
$7.6 107/kg; P5 .08) appeared to be a predictor for
the occurrence of aGVHD. CIF of cGVHD at 3 years
was 36% (10 extensive; and 12 limited). HLA match-
ing did not have an impact on the incidence of
aGVHD or cGVHD.
EFS and OS
The probability of 3-year EFS and 3-year OS rate
after unrelated CB transplantation were 70% and
77%, respectively. The probability of 3-year EFS (in
univariate analyses) was positively influenced by
a shorter interval between diagnosis and transplanta-tion (P5 .007) and a conditioning regimen containing
Bu/Cy (P 5 .002). Additionally, fully matched (6/6)
grafts were associated with 100% EFS (P 5 .06) com-
pared to 65% 6 7% and 64% 6 10%, for 5/6 and 4/6
matched grafts, respectively. The results are also illus-
trated by Kaplan-Meier curves and Log Rank test de-
picted in Figure 1b-d. Importantly, multivariate
analysis also demonstrated that both the interval be-
tween diagnosis and transplantation as well as the con-
ditioning regimen were statistically associated with
better 3-year EFS (P 5 .046 and P 5 .011, respec-
tively). HLA-matching was not significant in multivar-
iate analyses (P 5 .2). In this group of patients
receiving relatively high cell doses from theUCB graft,
cell dose was not predictive of survival (Table 3). No
uni- and multivariate predictors were found concern-
ing the endpoint probability of 3-year OS.
Enzyme replacement therapy (given in 23 patients
prior to CBT) was not found to be a predictor for any
of the endpoints, although there appears to be trend
for higher EFS (83 6 8 versus 63 6 6: P 5 .19) and
lower GVHD (19 6 9 versus 35 6 6: P 5 .16) in
the ERT group. Engraftment was not influenced by
ERT.Causes of Death
Twenty-one patients (23%) died within 3 years
post-SCT, 18 from a transplantation related cause (5
viral infection, 3 hemorrhage, 3 multiorgan failure, 3
graft failure, 2 acute respiratory distress syndrome, 1
GVHD, 1 interstitial pneumonitis), and 1 from disease
progression after graft failure. In 2 patients, the cause
of death was unknown.
Table 3. Multivariate Predictors of 3-Year EFS and Neutro-
phil Recovery after First CBT
3-Year EFS
HR 95% CI P-Value
Interval Dx - Tx <4.6 versus
$4.6 (months)
2.4 1.0-5.7 .046
Conditioning regimen
Bu/Cy versus other
0.3 0.1-0.7 .011
HLA-disparity identical
versus mismatched
1.8 0.7-4.3 .200
NC dose* <7.6 versus$7.6
(107/kg)
0.9 0.4-1.9 .737
Neutrophil Recovery
HR 95% CI P-Value
Age at Tx <1.3 versus $1.3
(years)
0.5 0.3-0.9 .010
CD34+ dose* < 2.6 versus
$ 2.6 (105/kg)
2.1 1.3-3.4 .002
Year at Tx <2004 versus
$2004
1.4 0.9-2.1 .188
CI indicates confidence intervals; Dx, diagnosis; EFS, Event-free survival;
HLA, human leucocyte antigen; HR, hazard ratio; NC, nucleated cell; Tx,
stem cell transplantation; CBT, cord blood transplantation
*At infusion. Statistically significant P-values are underlined.
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This Eurocord-Duke University collaborative
study on the outcomes of cord blood transplants for
HS showed that a shorter interval between diagnosis
and transplant and a conditioning regimen containing
Bu/Cy predicted higher EFS rate. Importantly, almost
all ‘‘alive and engrafted’’ patients achieved full donor
chimerism and normal enzymes levels in circulating
leukocytes. These findings are particularly important
because high donor chimerism and enzyme levels
improve long-term functional outcomes of children
with HS [6,17,18]. Despite small numbers, 6/6
matched (class I on low and class II on high resolution)
CV grafts may improve the outcome as well. The rela-
tively high rate of cGVHD in this study, although
mainly limited, might be a concern.
Similar to findings from other studies [19-21],
a higher and faster neutrophil recovery was associated
with CB units providing a higher CD34 cell dose.
Although, the CD34 cell dose did not have an impact
on the OS or EFS. It is possible that if multiple CB
units are available, selecting a unit with a higher cell
dose may decrease the time to engraftment and some
of the risks associated with prolonged neutropenia.
In addition, younger age at transplantation was an
individual predictor for higher neutrophil recovery.
An explanation for this might be the stage of disease,
as GAG storage in the marrow is suggested to be a fac-
tor influencing the stem cells homing [22]. Younger
children might have less storage in the BM matrix.
Also, younger children are physically smaller and
tend to receive higher cell doses from the UCB graft.
Until recently, high rates of graft failure and mixed
chimerism were reported in studies analyzing the out-come of SCT for HS. A recent European retrospective
study showed that these graft failures were mainly
associated with RIC regimen and T cell depletion
[7]. In this largest study so far, including 146 HS
patients, mainly patients receiving BM or PBSC grafts
(about 90%) were analyzed. Recently, Prasad et al. [10]
demonstrated an 1-year and 5-year OS of 77.3% and
74.5%, respectively, in 45 HS patients receiving
a CB transplantation [10]. These results suggest that
graft outcomes are at least comparable to the outcomes
of non-T-depleted BM/PBSCs transplants (related
and unrelated) after myeloablative conditioning
reported previously (60%-75%) [7,17,23]. A compari-
son study in this rare disease, including the all HS
patients from the CIMBTR, (EMBT) Promise, and
Eurocord databases, receiving an unrelated/related
BM and unrelated CBT, would be the best way to
study the influence of cell source. Although not
statistically significant, probably because of small
numbers, but in line with other CB studies [21], using
HLA-matched cord blood grafts might influence the
outcome: all 13 HS patients receiving on intermediate
resolution typed fully matched graft are alive and hav-
ing full donor chimerism in this study. This suggests
that in the future, when CB banks have increased their
inventory, the outcomes of these transplants might
further improve. For HS, and probably for other
IEM as well, the rapid availability of an allogeneic
donor appears to be essential, because a longer time
interval between diagnosis and transplantation nega-
tively influences the EFS rate. This will probably not
only influence the graft outcome data, but also the lon-
ger term outcomes, because of progression of disease.
Obviously, it is important that these patients need to
be tolerating full-intensity conditioning. For those
who cannot, ERT might be used to improve patients’
tolerance of full-intensity conditioning, for example,
where there is a severe associated cardiomyopathy
[24]. As found in this study, as in others, ERT does
not worsen outcome [24,25], and might therefore be
considered in those having a poor clinical condition.
In this subgroup of patients it has been shown that
ERT can bring them in a better clinical condition
[24]. A higher performance scale prior to CBT will
probably influence the outcome of this subgroup, as
found by others [10]. But for those who can tolerate
a full ablative regimen, CBT should not be delayed.
Although the aGVHD and cGVHD rates in this
study are similar to children receiving a CBT for acute
leukemia [21], this might be a concern because HS
patients do not have any advantage from having
GVHD.Moreover, it has even been suggested that (ex-
tensive) cGVHDmight influence the longer term out-
comes (eg, neuropsychologic and orthopedic late
complications of allogeneic HSCT). In the recently
published European series on SCT in HS, reported
cGVHD rates were lower, but in that series the
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Figure 1. Kaplan-Meier curves for neutrophil recovery according to the number of CD34 cells infused/kg (a), EFS according to the delay between diagnosis
and transplantation (b), EFS according to the HLA donor-recipient match (c), and EFS according to conditioning regimen before transplantation (d).
Biol Blood Marrow Transplant 15:618-625, 2009 623CBT in Hurler’s Syndromeproportion of patients with mixed chimerism was high
(30%) [7]. Others reported rates similar as found in
this cord blood study [17,26], but these reported data
are relatively old in comparison to the European series:
worse matching marrow grafts and other transplant
practices, like including total body irradiation (TBI)
in the conditioning of these young children, might
have influenced the GVHD rates as well. On the other
hand, in adults, comparing outcomes of matched BM
versus CB in a recent meta-analyses showed a favorable
effect of using CB on the incidence of cGVHD [27].
Comparison studies of the outcomes (graft outcomes
and long-term outcome parameters) of unrelated mar-
row versus unrelated cord blood versus matched sib-
ling donor, may help resolve the question about the
impact of graft source on the incidence of cGVHD.
Selection of higher matched donors when the CB
banks have extended their inventory or better post-
SCT immunosuppressive treatment for this group of
patients, might be strategies to influence the occur-
rence of cGVHD in these children. Limiting the cell
dose of the infused CB graft might be a strategy as
well, because an infused nucleated cell (NC) dose
.7.6  107/kg showed to be a trend to higher inci-
dence of GVHD.High rates of full donor chimerism and normal
enzyme levels were found in this study, demonstrating
that the use of unrelated cord blood is highly associated
with higher sustained engraftment inHS patients com-
pared to patients receiving BM as a stem cell source
[28]. In studies using BM, the mixed chimerism rate
ranged between 30% and 40%. These high rates of
full donor chimerism after CBT have been reported
in other studies on ‘‘CBT in IEM’’ as well [8-11].
This is an intriguing observation, and might suggest
a stronger ‘‘graft-versus-marrow’’ effect of CB cells in
comparison to BM/PBSC. The higher degree of
HLA-mismatch of the CB grafts (a majority of 1 or 2
mismatches on intermediate resolution typing), might
exert this stronger graft-versus-marrow effect without
increasing the rate of GVHD. In other words, the
‘‘window’’ between a strong graft-versus-marrow and
clinical GVHD might be wider, probably because of
the more naı¨ve phenotype of the T cell in the CB graft.
This probably stronger ‘‘graft-versus-marrow effect’’ is
in line with the lower incidence of relapses after mis-
matched CBT in children with acute leukemia in com-
parison to BM [21]. Alternatively, CB-derived natural
killer (NK) cells have been demonstrated to be func-
tionally ‘‘mature’’ with comparison of even better
624 Biol Blood Marrow Transplant 15:618-625, 2009J. J. Boelens et al.cytolytic activity compared with the BM-derived NK
cells [29,30]. This might exert a stronger graft-ver-
sus-marrow effect as well. Another explanation might
be the more pluripotential capability of the CB stem
cell, relative to the adult BM/PB stem cell, with higher
proliferative potentials [31-33]. Some animal studies
have demonstrated that the addition of mesenchymal
stem cells to the SCT product results in less graft rejec-
tion, because of the immunomodulating potential of
these cells [34,35]. Because mixed chimerism is associ-
atedwith lower leukocyte enzyme levels, which in turn,
leads to worse long-term outcomes, the level of donor
chimerismmight be an important aspect in the decision
on selecting a graft. Further studies to determine the
impact of cell source and enzyme levels on the long-
term outcomes in neuropsychologic, orthopedic, car-
diac, and other organ systems should be carried out.
In conclusion, unrelated cord blood is a good alter-
native stem cell source for SCT in HS patients, and it
might even be the preferred cell source. This is because
unrelated cord blood transplantation is (1) associated
with full donor chimerism in almost all engrafted
patients, which might influence the long-term out-
comes; (2) because of its fast availability and the fact
that it appears that the interval between diagnoses
and transplantation positively influences the outcome.
A concern however, might be the relatively higher rate
of, mainly limited, cGVHD found in this study. Better
matching and selection possibilities in the futuremight
further improve these outcomes by increasing the
number of CB units banked.ACKNOWLEDGMENTS
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